Sionna Therapeutics Inc(US:SION)2025-11-05 12:14Financial Performance - Net loss for Q3 2025 was $20.3 million, compared to a net loss of $25.4 million in Q3 2024[8] - Total operating expenses for Q3 2025 were $23.8 million, compared to $28.0 million in Q3 2024[15] Research and Development - Research and development expenses for Q3 2025 were $16.0 million, down from $24.6 million in Q3 2024, primarily due to one-time charges in the prior year[7] - Initiated PreciSION CF Phase 2a trial for SION-719 in October 2025, with topline data anticipated in mid-2026[4] - Initiated Phase 1 trial for SION-451 in dual combinations in August 2025, with topline data also expected in mid-2026[4] - The FDA cleared an Investigational New Drug (IND) application for SION-451, supporting its advancement to later-stage development[4] - SION-719 and SION-451 were generally well tolerated in Phase 1 trials, exceeding target exposure levels[5] Administrative Expenses - General and administrative expenses increased to $7.8 million in Q3 2025 from $3.4 million in Q3 2024, mainly due to personnel-related costs and professional fees[8] Cash and Assets - Cash, cash equivalents, and marketable securities totaled $325.0 million as of September 30, 2025, expected to fund operations into 2028[9] - Total assets as of September 30, 2025, were $339.3 million, up from $185.8 million at the end of 2024[17]